rss
Thorax 65:837-841 doi:10.1136/thx.2009.133355
  • Review

Treatment of COPD: the sooner the better?

  1. Christopher B Cooper2
  1. 1Respiratory Division, University of Leuven, Belgium
  2. 2Respiratory Division, David Geffen School of Medicine, University of California, Los Angeles, USA
  1. Correspondence to Marc Decramer, Respiratory Division, University Hospital, Herestraat 49, 3000 Leuven, Belgium; marc.decramer{at}uzleuven.be
  • Received 16 December 2009
  • Accepted 11 May 2010

Abstract

Classical belief is that only smoking cessation, and not pharmacotherapy, beneficially affect disease progression in chronic obstructive pulmonary disease (COPD). In recent years, new data on pharmacotherapy of COPD became available that shed new light on this question. The present paper reviews these data critically in an attempt to put them in a proper perspective. The most impressive new data are subgroup analyses of two large-scale long-term trials. With these new data it is now clear that patients in GOLD (Global Initiative for Chronic Obstructive Pulmonary Disease) stage II benefit as much from pharmacotherapy as patients in the later stages of the disease. Effects on prebronchodilator and postbronchodilator forced expiratory volume in 1 s (FEV1), health-related quality of life, exacerbations and hospitalisations appear at least as pronounced in GOLD stage II as in the other GOLD stages. In addition, evidence suggestive of an effect on disease progression is available in the sense of an effect on rate of decline of FEV1, and trends for reductions in mortality. Finally, good evidence is available that, in contrast to conventional thinking, decline of FEV1 occurs at a considerably faster rate in the early stages of the disease. These data together with the high prevalence of co-morbidities from early in the disease onwards provide us with strong suggestive evidence for early intensive intervention in COPD. New trials, particularly demonstrating the detrimental effects of delaying treatment until later in the course of the disease, are required to render the evidence for early intensive intervention irrefutable.

Footnotes

  • Competing interests MD received consulting fees from Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Nycomed and AstraZeneca, lecture fees from Boehringer Ingelheim, Pfizer and Novartis, and grant support from AstraZeneca. CBC has received consulting fees from Boehringer Ingelheim, Dey Pharmaceuticals, Pfizer and Forest, lecture fees from AstraZeneca, Boehringer Ingelheim, Dey Pharmaceuticals and Pfizer, and grant support from Boehringer Ingelheim, CSL-Behring and Pfizer.

  • Ethics approval This study was conducted with the approval of the ethics committee of the appropriate university hospitals.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Received 16 December 2009
  • Accepted 11 May 2010